A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination With Everolimus in Advanced Ovarian and Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Niraparib (Primary)
- Indications Advanced breast cancer; Ovarian cancer
- Focus Adverse reactions
- 23 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Aug 2019.
- 29 Nov 2017 Status changed from not yet recruiting to recruiting.
- 19 May 2017 New trial record